Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study

IntroductionClinical remission as a multicomponent treatment goal in severe asthma is being explored in clinical practice. This post hoc analysis used data from the REDES study to assess the proportion of patients with severe eosinophilic asthma achieving our multicomponent definitions of clinical r...

Повний опис

Бібліографічні деталі
Автори:	Ian Pavord, Frances Gardiner, Liam G. Heaney, Christian Domingo, Robert G. Price, Alison Pullan, John Oppenheimer, Guy Brusselle, Hiroyuki Nagase, Geoffrey Chupp, Emilio Pizzichini, David Bañas-Conejero, Peter Howarth
Формат:	Стаття
Мова:	English
Опубліковано:	Frontiers Media S.A. 2023-04-01
Серія:	Frontiers in Immunology
Предмети:	severe asthma remission clinical outcomes real-world eosinophil biology mepolizumab
Онлайн доступ:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1150162/full

Схожі ресурси

A Case of Eosinophilic Gastroenteritis Remission Achieved Steroid-Free With Mepolizumab
за авторством: Yuki Hirata, та інші
Опубліковано: (2022-01-01)

Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study
за авторством: Masanobu Ueno, та інші
Опубліковано: (2022-06-01)

Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
за авторством: Mkorombindo T, та інші
Опубліковано: (2019-08-01)

Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with Mepolizumab
за авторством: Diego Bagnasco, та інші
Опубліковано: (2024-04-01)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
за авторством: Steven W. Yancey, та інші
Опубліковано: (2019-09-01)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
за авторством: Haldar P
Опубліковано: (2017-06-01)

Mepolizumab-responsive recurrent eosinophilic eruption without peripheral eosinophilia
за авторством: Nina B. Curkovic, MD, та інші
Опубліковано: (2024-11-01)

The clinical question of mepolizumab in the long-term treatment of idiopathic chronic eosinophilic pneumonia; how long should we use mepolizumab?
за авторством: Masamitsu Hamakawa, та інші
Опубліковано: (2024-01-01)

Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis
за авторством: Masanobu Ueno, та інші
Опубліковано: (2021-03-01)

Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty
за авторством: Ryota Otoshi, та інші
Опубліковано: (2020-03-01)

Clinical efficacy of mepolizumab in the treatment of severe eosinophilic asthma in children
за авторством: V. N. Drozdov, та інші
Опубліковано: (2020-11-01)

Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis
за авторством: Giuseppe A. Ramirez, та інші
Опубліковано: (2022-12-01)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
за авторством: Pelaia C, та інші
Опубліковано: (2017-10-01)

May mepolizumab used in asthma correct subfertility?
за авторством: Guzin Ozden, та інші
Опубліковано: (2021-01-01)

Allergic bronchopulmonary aspergillosis complicated by eosinophilic chronic rhinosinusitis successfully treated with mepolizumab
за авторством: Nobuhiro Matsumoto, та інші
Опубліковано: (2019-10-01)

Experience with mepolizumab in adults with severe eosinophilic asthma: a case series from India
за авторством: Venkata Nagarjuna Maturu, та інші
Опубліковано: (2021-08-01)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
за авторством: Takanori Numata, та інші
Опубліковано: (2019-10-01)

Clinical Remission Criteria and Serum Levels of Type 2 Inflammation Mediators during 24 Weeks of Treatment with the Anti-IL-5 Drug Mepolizumab in Patients with T2-High Severe Asthma
за авторством: Jolita Palacionyte, та інші
Опубліковано: (2024-06-01)

Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
за авторством: Alistair Cook, та інші
Опубліковано: (2021-05-01)

Predictors of the enhanced response to mepolizumab treatment for severe eosinophilic asthma: A retrospective, long-term study
за авторством: Takanori Numata, та інші
Опубліковано: (2020-01-01)

Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study
за авторством: Kenneth R. Chapman, та інші
Опубліковано: (2024-02-01)

Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
за авторством: I. J. Pouliquen, та інші
Опубліковано: (2017-11-01)

Mepolizumab para el tratamiento de asma grave eosinofílica
за авторством: Armando Partida-Gaytán, та інші
Опубліковано: (2021-01-01)

When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report
за авторством: M. Sabbe, та інші
Опубліковано: (2024-01-01)

Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan
за авторством: Takashi Yamane, та інші
Опубліковано: (2023-06-01)

Mepolizumab Therapy for Recalcitrant Eosinophilic Annular Erythema in an Adult: A Case Report and Review of Treatment Options
за авторством: Magdalena Żychowska, та інші
Опубліковано: (2020-06-01)

Case Report: Mepolizumab in the treatment of idiopathic chronic eosinophilic pneumonia [version 3; peer review: 2 approved]
за авторством: Moetemri Zied, та інші
Опубліковано: (2023-09-01)

Real-world outcomes of mepolizumab treatment in severe eosinophilic asthma patients - retrospective cohort study in Slovakia
за авторством: Milos Jesenak, та інші
Опубліковано: (2023-09-01)

Idiopathic hypereosinophilic syndrome with eosinophilic cellulitis-like cutaneous involvement treated with mepolizumab and dapsone
за авторством: Madeleine Lachance, MD, та інші
Опубліковано: (2022-04-01)

Combination effect of Mepolizumab and Endobronchial Watanabe Spigot (EWS) in drug‐induced eosinophilic pneumonia complicated by refractory pneumothorax
за авторством: Nana Ayame, та інші
Опубліковано: (2024-09-01)

Switching from omalizumab to mepolizumab therapy improved extra‐pulmonary abdominal and cutaneous vasculitis symptoms in a patient with eosinophilic granulomatosis with polyangiitis
за авторством: Yu‐Hsuan Chen, та інші
Опубліковано: (2022-01-01)

Role of mepolizumab in severe allergic asthma with vocal cord polyp
за авторством: Azmat Karim, та інші
Опубліковано: (2022-01-01)

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series
за авторством: Carlo Lombardi, та інші
Опубліковано: (2024-07-01)

Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions
за авторством: Peter G. Gibson, та інші
Опубліковано: (2021-06-01)

Severe asthma remaining well‐controlled after mepolizumab discontinuation: A case report and literature review
за авторством: Takahiro Matsuyama, та інші
Опубліковано: (2023-06-01)

Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis
за авторством: Nami Masumoto, та інші
Опубліковано: (2023-05-01)

Severe eosinophilic bronchial asthma: new therapeutic options
за авторством: N. M. Nenasheva
Опубліковано: (2018-10-01)

Low-dose anti-IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance
за авторством: Marco Caminati, та інші
Опубліковано: (2023-09-01)

Gastrointestinal Involvement of Eosinophilic Granulomatosis with Polyangiitis with Histological Evidence of Treatment Response
за авторством: Mark Lai, та інші
Опубліковано: (2023-03-01)

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma
за авторством: Manuel David Gil-Sierra, та інші
Опубліковано: (2019-11-01)